Clinical Trials > PANASTA  

  • Information
  • Treatment
  • Endpoints
  • Eligibility
  • Sites - Open
  • Sites - Interested
  • Links


Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pacreato-duodenectomy – a double blinded multi-centred trial (Phase III).

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
III Surgical Closed UoL Eudract No:
Isrctn No: ISRCTN52263879

Trial Start Date


Trial Coordinator

Kellie Platt

Trial Coordinator Email Address

Trial Coordinator Contact No

0151 794 8897

Website Treatment  

Patients will be randomised 1:1 to receive one of the two treatment arms, which are different methods of constructing a pancreatico-jejunostomy in the reconstruction of the pancreatic remnant following pancreato-duodenectomy.

Trial Endpoints  

Primary Outcome  

This is the presence or absence of a post-operative pancreatic fistula (POPF) as defined by Bassi et al. [14]. For the purpose of this study all classes of fistula will be recorded. POPF are defined as any abnormal connection between the pancreatic duct epithelium and another epithelised surface, which contains pancreatic derived, enzyme rich fluid. POPF need to satisfy the following criteria:
? Output of a measurable volume of fluid via either a drain placed per-operatively or via subsequent placed interventional drain.
? On or after post-operative day 3
? Amylase content greater than 3 times the institutional upper limit of normal.

Secondary Outcomes  

  • Entry into programs of adjuvant therapy/clinical trials of adjuvant therapy
  • Mortality rate
  • Pancreas specific complications
  • Non-Pancreas specific complications
  • Assessment of quality of life
  • Health economic evaluation


 Inclusion Criteria
Subjects meeting all of the following criteria will be considered for this trial:
? Patients undergoing an elective pancreato-duodenectomy for presumed malignancy.
? Ability of the subject to understand the nature and consequences of the trial.
? Ability to provide written informed consent.

Exclusion Criteria
Subjects with the following criteria will not be entered into this trial:
? Patients undergoing extended pancreato-duodenectomy
? Left, central or total pancreatectomy
? Arterial resection or multi-visceral resection
? Previous pancreatic resection
? Surgery for known chronic pancreatitis
? Recruited to any other pancreatic resection trial.
? Pregnant women


  • , Churchill Hospital (Oxford) (Srikanth Reddy)
  • , Queen's Medical Centre (Nottingham) (Dhanny Gomez)
  • Leeds, St. James University Hospital (Leeds) (Andrew Smith)
  • Liverpool, Royal Liverpool University Hospital (Christopher Halloran)
  • London, King's College Hospital (London) (Andreas Prachalias)

UK: England

  • London, Royal Free Hospital (London) (Brian Davidson)
  • Manchester , Manchester Royal Infirmary (Derek O'Reilly)

UK: Wales

  • Swansea, Morriston Hospital (Swansea) (Bilal Al-Sarireh)


  • , Mater Infirmorium Hospital (Belfast) (Mark Taylor)


  • , Aberdeen Royal Infirmary (Irfan Ahmed)



We would like to inform all patients who consented to take part in the PANasta trial of an error in the information we provided you relating to the data collected about you.

The Information Sheet that was provided to you before you agreed to take part we stated that “Any data sent to the Liverpool Cancer Trials Unit will not contain any identifiable information (name, date of birth, address, hospital number) i.e. anonymised data.”

This was incorrect.  The LCTC (previously LCTU) collected date of birth from patients when they started the trial.  This data was used to calculate your age only and WILL NOT be referenced in any trial related publication.  

All data continues to be appropriately stored in accordance with the Data Protection Act 2018 and remains strictly confidential.



Lost Username / Password?